Evidence map›Paper›PMID 26487947›Full record

ArticleJournal of gastrointestinal oncology2015

Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center.

Danielle S Bitterman, David Grew, Ping Gu, Richard F Cohen, Nicholas J Sanfilippo, Cynthia G Leichman, Lawrence P Leichman, Harvey G Moore, Heather T Gold, Kevin L Du

Abstract read
In one paragraph

Article in Journal of gastrointestinal oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Danielle S Bitterman1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
David Grew1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Ping Gu1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Richard F Cohen1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Nicholas J Sanfilippo1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Cynthia G Leichman1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Lawrence P Leichman1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Harvey G Moore1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Heather T Gold1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
Kevin L Du1 Department of Radiation Oncology, 2 Division of Hematology and Medical Oncology, Department of Medicine, 3 Division of Colon and Rectal Surgery, Department of Surgery, 4 Department of Population Health, New York University Langone Medical Center, New York, NY 10016, USA.
NYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare clinical and treatment characteristics and outcomes in locally advanced anal cancer, a potentially curable disease, in patients referred from a public or private hospital.

methodsWe retrospectively reviewed 112 anal cancer patients from a public and a private hospital who received definitive chemoradiotherapy at the same cancer center between 2004 and 2013. Tumor stage, radiotherapy delay, radiotherapy duration, and unplanned treatment breaks ≥10 days were compared using t-test and χ(2) test. Overall survival (OS), disease free survival (DFS), and colostomy free survival (CFS) were examined using the Kaplan-Meier method and compared with the log-rank test. Cox proportional hazard models for OS and DFS were developed.

resultsThe follow-up was 14.9 months (range, 0.7-94.8 months). Public hospital patients presented with significantly higher clinical T stage (P<0.05) and clinical stage group (P<0.05), had significantly longer radiotherapy delays (P<0.05) and radiotherapy duration (P<0.05), and had more frequent radiation therapy (RT) breaks ≥10 days (P<0.05). Three-year OS showed a marked trend in favor of private hospital patients for 3-year OS (72.8% vs. 48.9%; P=0.171), 3-year DFS (66.3% vs. 42.7%, P=0.352), and 3-year CFS (86.4% vs. 68.9%, P=0.299). Referral hospital was not predictive of OS or DFS on multivariate analysis.

conclusionsPublic hospital patients presented at later stage and experienced more delays in initiating and completing radiotherapy, which may contribute to the trend in poorer DFS and OS. These findings emphasize the need for identifying clinical and treatment factors that contribute to decreased survival in low socioeconomic status (SES) populations.

Indexed as

Anal cancerpublic hospitalsradiotherapy, socioeconomic factorstreatment outcome

Identifiers

PMID26487947
PMCPMC4570920
OpenAlexW2193126189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.